Bimatoprost vs latanoprost

Individually Bimatoprost, Latanoprost and Travoprost significantly lowered the intraocular pressure but this reduction was not population (4% vs. 1.6

latanoprost vs bimatoprost), fewer reported hyperemia (P.001, latanoprost vs bimatoprost), and average hyper-emia scores were lower at week

Patients on latanoprost requiring lower IOP achieved a greater additional short-term diurnal IOP reduction when latanoprost was replaced by bimatoprost compared with travoprost. Low rates of hyperaemia were observed in patients treated with bimatoprost or travoprost after switching from latanoprost.

travoprost (Travatan) versus latanoprost solution (Xalatan) versus bimatoprost. (Lumigan). Travoprost 0.004%, bimatoprost 0.03%, and

Latanoprost is more susceptible to degradation at elevated temperature than bimatoprost. Bimatoprost also has the advantage of being available as a powder

Fewer latanoprost-treated patients reported ocular adverse events (P .001, latanoprost vs bimatoprost), fewer reported hyperemia (P =.001, latanoprost vs bimatoprost), and average hyperemia scores were lower at week 12 (P =.001, latanoprost vs bimatoprost).

In a 3-month bimatoprost versus latanoprost trial, eyelash growth was more common in the bimatoprost group (13% bimatoprost vs. 4% latanoprost). 6 Hypertrichosis appears to occur earlier during bimatoprost treatment as compared to latanoprost. This may be because of the possibility that bimatoprost, unlike latanoprost, does not need to be

Patients on latanoprost monotherapy who required additional IOP lowering discontinued latanoprost and were randomized to bimatoprost 0.03% (?

versus latanoprost solution (Xalatan), versus Bimatoprost (Lumigan), latanoprost solution (Xalatan), latanoprostene bunod (Vyzulta), and